The drug combination SUNITINIB and LAPATINIB acted synergistically against the human ovarian cancer cell line SKOV3, modulating the PI3K/AKT/mTOR pathway corresponding to SUNITINIB and inhibiting HER2 target proteins corresponding to LAPATINIB, which inhibited SKOV3 cell proliferation and tumor growth (Komarova et al. 2011, Yang et al. 2017). The gene discussed is ERBB2; the disease is ovarian cancer.